Claude on Cannabis
I Asked Claude on Cannabis
To Claude: When has the Drug Enforcement Agency requested a Government Accountability Office report in the past that resulted in rescheduling of a drug?
Researching DEA-requested GAO reports on drug rescheduling.
I’m not aware of any case like that, and the question rests on a premise that doesn’t match how the process works.
GAO doesn’t work for DEA. The Government Accountability Office is a legislative-branch agency that works for Congress. GAO reports are typically requested by congressional committees or members, or mandated by statute, not by executive agencies like DEA.
Rescheduling doesn’t run through GAO. Under the Controlled Substances Act, rescheduling is initiated by DEA, HHS, or a petition. HHS (through FDA and NIDA) then does a scientific and medical evaluation and makes a binding recommendation on the scientific and medical findings. DEA then decides and, if it acts, does so through notice-and-comment rulemaking. GAO has no formal role.
Where GAO has mattered. GAO has published reports touching on DEA’s scheduling and related work, such as drug shortages and the quota system for Schedule I and II substances, DEA’s diversion control, and marijuana research barriers. Those reports fed congressional oversight, but I’m not aware of any that directly triggered a rescheduling. Well-known rescheduling actions, like moving hydrocodone combination products from Schedule III to II in 2014, were driven by the HHS/FDA review process and DEA rulemaking.
If you saw this claim somewhere specific, such as a particular drug or a news article, tell me and I can dig into it. I can also search for GAO reports on DEA scheduling if you want the actual list, since my recollection of specific report titles may be incomplete.
Positions: None.
